Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Genomic ALK alterations in primary and relapsed neuroblastoma.
British Journal Of Cancer
Rosswog, Carolina C; Fassunke, Jana J; Ernst, Angela A; Schömig-Markiefka, Birgid B; Merkelbach-Bruse, Sabine S; Bartenhagen, Christoph C; Cartolano, Maria M; Ackermann, Sandra S; Theissen, Jessica J; Blattner-Johnson, Mirjam M; Jones, Barbara B; Schramm, Kathrin K; Altmüller, Janine J; Nürnberg, Peter P; Ortmann, Monika M; Berthold, Frank F; Peifer, Martin M; Büttner, Reinhard R; Westermann, Frank F; Schulte, Johannes H JH; Simon, Thorsten T; Hero, Barbara B; Fischer, Matthias M
Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report.
Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation.
Diagnostics (Basel, Switzerland)
Djos, Anna A; Treis, Diana D; Fransson, Susanne S; Gordon Murkes, Lena L; Wessman, Sandra S; Ásmundsson, Jurate J; Markström, Agneta A; Kogner, Per P; Martinsson, Tommy T
Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors.
Iscience
Inam, Haider H; Sokirniy, Ivan I; Rao, Yiyun Y; Shah, Anushka A; Naeemikia, Farnaz F; O'Brien, Edward E; Dong, Cheng C; McCandlish, David M DM; Pritchard, Justin R JR
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
Jto Clinical And Research Reports
Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.
Proceedings Of The National Academy Of Sciences Of The United States Of America
van den Boogaard, Marlinde L ML; Oka, Rurika R; Hakkert, Anne A; Schild, Linda L; Ebus, Marli E ME; van Gerven, Michael R MR; Zwijnenburg, Danny A DA; Molenaar, Piet P; Hoyng, Lieke L LL; Dolman, M Emmy M MEM; Essing, Anke H W AHW; Koopmans, Bianca B; Helleday, Thomas T; Drost, Jarno J; van Boxtel, Ruben R; Versteeg, Rogier R; Koster, Jan J; Molenaar, Jan J JJ
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology
Bellini, Angela A; Pötschger, Ulrike U; Bernard, Virginie V; Lapouble, Eve E; Baulande, Sylvain S; Ambros, Peter F PF; Auger, Nathalie N; Beiske, Klaus K; Bernkopf, Marie M; Betts, David R DR; Bhalshankar, Jaydutt J; Bown, Nick N; de Preter, Katleen K; Clément, Nathalie N; Combaret, Valérie V; Font de Mora, Jaime J; George, Sally L SL; Jiménez, Irene I; Jeison, Marta M; Marques, Barbara B; Martinsson, Tommy T; Mazzocco, Katia K; Morini, Martina M; Mühlethaler-Mottet, Annick A; Noguera, Rosa R; Pierron, Gaelle G; Rossing, Maria M; Taschner-Mandl, Sabine S; Van Roy, Nadine N; Vicha, Ales A; Chesler, Louis L; Balwierz, Walentyna W; Castel, Victoria V; Elliott, Martin M; Kogner, Per P; Laureys, Geneviève G; Luksch, Roberto R; Malis, Josef J; Popovic-Beck, Maja M; Ash, Shifra S; Delattre, Olivier O; Valteau-Couanet, Dominique D; Tweddle, Deborah A DA; Ladenstein, Ruth R; Schleiermacher, Gudrun G
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Nature Communications
Brady, Samuel W SW; Liu, Yanling Y; Ma, Xiaotu X; Gout, Alexander M AM; Hagiwara, Kohei K; Zhou, Xin X; Wang, Jian J; Macias, Michael M; Chen, Xiaolong X; Easton, John J; Mulder, Heather L HL; Rusch, Michael M; Wang, Lu L; Nakitandwe, Joy J; Lei, Shaohua S; Davis, Eric M EM; Naranjo, Arlene A; Cheng, Cheng C; Maris, John M JM; Downing, James R JR; Cheung, Nai-Kong V NV; Hogarty, Michael D MD; Dyer, Michael A MA; Zhang, Jinghui J
Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma.
Genome Research
Lopez, Gonzalo G; Conkrite, Karina L KL; Doepner, Miriam M; Rathi, Komal S KS; Modi, Apexa A; Vaksman, Zalman Z; Farra, Lance M LM; Hyson, Eric E; Noureddine, Moataz M; Wei, Jun S JS; Smith, Malcolm A MA; Asgharzadeh, Shahab S; Seeger, Robert C RC; Khan, Javed J; Auvil, Jaime Guidry JG; Gerhard, Daniela S DS; Maris, John M JM; Diskin, Sharon J SJ
Publication Date: 2020-09
Variant appearance in text: ALK: 3520T>A; Phe1174Ile
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association
Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Scientific Reports
Javanmardi, Niloufar N; Fransson, Susanne S; Djos, Anna A; Sjöberg, Rose-Marie RM; Nilsson, Staffan S; Truvé, Katarina K; Kogner, Per P; Martinsson, Tommy T
Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Nature
Ma, Xiaotu X; Liu, Yu Y; Liu, Yanling Y; Alexandrov, Ludmil B LB; Edmonson, Michael N MN; Gawad, Charles C; Zhou, Xin X; Li, Yongjin Y; Rusch, Michael C MC; Easton, John J; Huether, Robert R; Gonzalez-Pena, Veronica V; Wilkinson, Mark R MR; Hermida, Leandro C LC; Davis, Sean S; Sioson, Edgar E; Pounds, Stanley S; Cao, Xueyuan X; Ries, Rhonda E RE; Wang, Zhaoming Z; Chen, Xiang X; Dong, Li L; Diskin, Sharon J SJ; Smith, Malcolm A MA; Guidry Auvil, Jaime M JM; Meltzer, Paul S PS; Lau, Ching C CC; Perlman, Elizabeth J EJ; Maris, John M JM; Meshinchi, Soheil S; Hunger, Stephen P SP; Gerhard, Daniela S DS; Zhang, Jinghui J
A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Frontiers In Immunology
Toor, Jugmohit S JS; Rao, Arjun A AA; McShan, Andrew C AC; Yarmarkovich, Mark M; Nerli, Santrupti S; Yamaguchi, Karissa K; Madejska, Ada A AA; Nguyen, Son S; Tripathi, Sarvind S; Maris, John M JM; Salama, Sofie R SR; Haussler, David D; Sgourakis, Nikolaos G NG
ARID1B alterations identify aggressive tumors in neuroblastoma.
Oncotarget
Lee, Soo Hyun SH; Kim, Jung-Sun JS; Zheng, Siyuan S; Huse, Jason T JT; Bae, Joon Seol JS; Lee, Ji Won JW; Yoo, Keon Hee KH; Koo, Hong Hoe HH; Kyung, Sungkyu S; Park, Woong-Yang WY; Sung, Ki W KW
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
Genome Research
Brammeld, Jonathan S JS; Petljak, Mia M; Martincorena, Inigo I; Williams, Steven P SP; Alonso, Luz Garcia LG; Dalmases, Alba A; Bellosillo, Beatriz B; Robles-Espinoza, Carla Daniela CD; Price, Stacey S; Barthorpe, Syd S; Tarpey, Patrick P; Alifrangis, Constantine C; Bignell, Graham G; Vidal, Joana J; Young, Jamie J; Stebbings, Lucy L; Beal, Kathryn K; Stratton, Michael R MR; Saez-Rodriguez, Julio J; Garnett, Mathew M; Montagut, Clara C; Iorio, Francesco F; McDermott, Ultan U
Holla, Vijaykumar R VR; Elamin, Yasir Y YY; Bailey, Ann Marie AM; Johnson, Amber M AM; Litzenburger, Beate C BC; Khotskaya, Yekaterina B YB; Sanchez, Nora S NS; Zeng, Jia J; Shufean, Md Abu MA; Shaw, Kenna R KR; Mendelsohn, John J; Mills, Gordon B GB; Meric-Bernstam, Funda F; Simon, George R GR
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Disease Models & Mechanisms
Guan, J J; Tucker, E R ER; Wan, H H; Chand, D D; Danielson, L S LS; Ruuth, K K; El Wakil, A A; Witek, B B; Jamin, Y Y; Umapathy, G G; Robinson, S P SP; Johnson, T W TW; Smeal, T T; Martinsson, T T; Chesler, L L; Palmer, R H RH; Hallberg, B B
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Oncotarget
Amin, Amit Dipak AD; Li, Lingxiao L; Rajan, Soumya S SS; Gokhale, Vijay V; Groysman, Matthew J MJ; Pongtornpipat, Praechompoo P; Tapia, Edgar O EO; Wang, Mengdie M; Schatz, Jonathan H JH